Rajesh is a scientific key opinion leader with 25+ years in drug development, specializing in model-informed strategies for biologics, vaccines, and small molecules. Currently a Senior Distinguished Scientist at Certara, he leads strategic consulting and the CDDS centers of excellence. Previously, he founded Merck’s quantitative clinical pharmacology department and held key roles at Aventis and Bristol-Myers Squibb. Rajesh holds a PhD in Pharmaceutical Sciences (University of British Columbia) and an MBA in Strategy and Innovation (Warwick). Consistently recognized among the top 2% of influential scientists, his work includes 100+ publications, 89 posters, and 4 books. He is an elected fellow of AAPS.
Rajesh Krishna, PhD
Senior Distinguished Scientist, Drug Development Solutions
More resources by Rajesh Krishna, PhD
Key development considerations for cell therapies
Blog
Why Clinical Pharmacology & Pharmacometrics Should Collaborate
Blog
Resmetirom: A pioneering NASH clinical program
Blog
How does a clinical development plan help drug programs?
Blog
Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates
Blog
What are biosimilars & how are they developed?
Blog
Understanding the Role of Your Discovery Asset’s Target Product Profile
Blog
Methods to Increase Signal Finding in Rare Disease Drug Development
Blog
Stop if you don’t have an unambiguous drug effect for your new molecular entity!
Blog
Drug Development Considerations for Live Biotherapeutic Products
Blog
Artificial Intelligence: What is it & how can it accelerate rare disease drug development?
Blog
Why you should select your drug formulation before starting clinical studies
Blog
Why are Human Radiolabeled Mass-balance Studies Important in Clinical Pharmacology & Drug Development?
Blog
Why FDA’s New Guidance on Circulating Tumor DNA is Critical for Oncology Early Clinical Drug Development
Blog
Reflections on the Recent ICH E11A Pediatric Extrapolation Guideline
Blog
The Utility of Model-Informed Drug Development for Rare Diseases
Blog
How to Fix Your Biggest Bioequivalence Mistakes
Blog
Experts Unravel the Top 5 Myths Related to Bioequivalence
Blog
Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development
Blog
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease
Blog
Developing Targeted Covalent Inhibitor Drugs: 3 Key Considerations
Blog
A Day in the Life of a Clinical Pharmacology Consultant
Blog
Building a Robust Clinical Pharmacology & Model-Informed Drug Development Strategy for New Alzheimer’s Disease Drugs
Blog
Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success
Blog
